Guerbet: Antoine Fady Becomes Chairman of the Board
On Friday, Guerbet announced a reshuffling of its board of directors following its general assembly on May 22, 2026. Antoine Fady has been appointed as the chairman of the board, with three new directors representing the majority shareholder also joining.
Antoine Fady has been appointed as an independent director and chairman of the board of directors of Guerbet, effective immediately. This appointment concludes his role as a censor, which he has held since March 11, 2026. A graduate engineer from the École nationale supérieure des Mines de Saint-Étienne and holder of an MBA from INSEAD, Fady has over ten years of experience as the CEO of Flint Group. He has also held various senior management positions at ICI and Akzo Nobel, particularly in the paints and coatings activities in Europe. His career also includes governance experience as a non-executive director and board chairman, including at Roquette (current mandate) and XSYS (chairman of the board from 2021 to 2024).
Three New Directors Representing the Majority Shareholder
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The general assembly appointed three new directors representing the majority shareholder. Emmanuelle Louvet replaces Nicolas Louvet, whose term has expired. Vincent Dagommer replaces Marc Massiot, who resigned. Olivier Guerbet replaces Carine Dagommer, whose term has also expired. The board of directors of Guerbet now consists of nine members: Antoine Fady (chairman of the board, independent director), Vincent Dagommer, Eric Drapé (independent director), Marie de la Simone (employee director), Eric Guerbet, Olivier Guerbet, Céline Lamort, Michèle Lesieur (independent director), and Emmanuelle Louvet.
Related
SectorDispositifs médicaux et optique›Dispositifs médicaux / imagerie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 573,8 millions d'euros
Quarterly revenue: 573,8 millions d'euros
Revenue growth: -2,2 %
Guidance from the release
Strongly negative free cash flow of between -€50 million and -€70 million, due to the expected decrease in restated EBITDA, the increase in the CAPEX plan and non-recurring restructuring costs
Risks mentioned
Ongoing contraction in sales in China due to policy to sharply reduce healthcare spending and gradual elimination of intermediaries
Planned slowdown in subcontracting activities at Gadopiclenol production site with Fill & Finish ending at end-2026
Continued normalisation at Raleigh industrial site with restructuring costs and redundancy plan in France
Opportunities identified
Strong momentum in Interventional Radiology business, up 6.6% with Lipiodol® driving growth in vascular embolization market
Recovery in activity in France and positive contribution from EMEA, Americas and Asia regions excluding China
Dynamic sales of Elucirem™ product offsetting some of the decline in other divisions
Outlook / guidance
Management commentary: For 2026, the Group's targets are: Revenue stable or showing a slight decrease at CER and on a like-for-like basis. Restated EBITDA margin rate of around 8%, including around €35 million related to the costs of the remediation plan at the Raleigh site. Strongly negative free cash flow of between -€50 million and -€70 million, due to the expected decrease in restated EBITDA, the increase in the CAPEX plan and non-recurring restructuring costs linked to the Group's transformation plan, including in particular the redundancy plan in France.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
